Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari(Icahn School of Medicine at Mount Sinai), Attaya Suvannasankha(Indiana University Health), Joseph W. Fay(Baylor University), Bertrand Arnulf(Assistance Publique – Hôpitaux de Paris), Jonathan L. Kaufman(Emory University), Jainulabdeen J. Ifthikharuddin(Strong Memorial Hospital), Brendan M. Weiss(University of Pennsylvania), Amrita Krishnan(City of Hope), Suzanne Lentzsch(Columbia University Irving Medical Center), Raymond L. Comenzo(Tufts Medical Center), Jianping Wang(Janssen (United States)), Kerri Nottage(Janssen (United States)), Christopher Chiu(Janssen (United States)), Nushmia Z. Khokhar(Janssen (United States)), Tahamtan Ahmadi(Janssen (United States)), Sagar Lonial(Emory University)
Cited by 442Open Access
Abstract
Among the 62 responders, median duration of response was not estimable (NE; 95% confidence interval [CI], 13.6-NE). At a median follow-up of 13.1 months, the median progression-free survival was 8.8 (95% CI, 4.6-15.4) months and median overall survival was 17.5 (95% CI, 13.3-NE) months. The estimated 12-month survival rate was 66% (95% CI, 55.6-74.8). Aside from increased neutropenia, the safety profile of daratumumab plus pom-dex was consistent with that of the individual therapies. Deep, durable responses were observed in heavily treated patients. The study was registered at www.clinicaltrials.gov as #NCT01998971.
Related Papers
No related papers found
Powered by citation graph analysis